Drug updated on 4/18/2024
| Dosage Form | Tablet (oral; 6 mg) |
| Drug Class | Tyrosine kinase 2 (TYK2) inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Summary
- Deucravacitinib (Sotyktu) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It has shown strong efficacy without compromising safety over a 12-to-16-week period, achieving significant improvements in PASI 75, ss-PGA 0/1, and DLQI 0/1 scores.
- Four studies were reviewed to gather information about Sotyktu's effectiveness and safety compared to other treatments for moderate-to-severe plaque psoriasis.
- When compared to PDE4 inhibitors like apremilast and another TYK2 inhibitor called Ropsacitinib, Sotyktu demonstrated higher efficacy based on PASI and PGA response rates. Specific dosages of this drug ranked highest as potential effective oral treatments.
- In terms of safety compared to placebo and Apremilast, Sotyktu showed better outcomes across several key endpoints with a low incidence of adverse events (AEs) and serious adverse events (SAEs), positioning it as a potential first-line oral therapy option.
- While Tofacitinib scored higher in both efficacy and safety among the JAK inhibitors class according to one study; however, deucravacitinib still showed considerable efficacy with competitive safety profiles, especially at higher doses such as 12 mg QD for achieving PASI75 & PGA responses.
- Specific population considerations were not extensively detailed, but patient demographics suggest broad applicability across adults suffering from moderate-to-severe psoriasis, including challenging subgroups like those with scalp involvement.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Sotyktu (deucravacitinib) prescribing information. | 2022 | Bristol-Myers Squibb Company Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Deucravacitinib for moderate-to-severe psoriasis: a systematic review and meta-analysis of randomized controlled trials. | 2024 | Journal of Drugs in Dermatology |
| Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis. | 2023 | Frontiers in Immunology |
| The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. | 2023 | Frontiers in Medicine |
| The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis. | 2022 | Journal of the European Academy of Dermatology and Venereology |